Translate 
Abstract
Against the background of increasing antibiotic resistance among pathogens of bovine bronchopneumonia, interest in phagotherapy as a therapeutic tool is revived. Inhaled phagotherapy in turn has the potential to change the treatment regimen for bacterial respiratory infections, including those caused by antibiotic-resistant bacteria. Inhaled drug delivery tools allow the delivery of bacteriophages directly to the lesion. An important advantage, especially when it comes to bacteriophages, is the ability to use smaller doses of drugs than would be required if another route of administration were chosen. The article presents the results of evaluating the efficacy of the inhalation method of administration of commercial bacteriophage preparations in a mouse model. Mice were divided into five groups (1,2-animals exposed to <I>Klebsiella pneumonia</I> infection and undergoing bacteriophage inhalation (n=6), 3-animals exposed to infection and not undergoing therapy (n=3), 4- control group of animals not exposed to infection (n=3)). Inhalations were performed using a compressor four-mode Neb-Aid inhaler (Flaem Nuova, Italy). Rapidflyam 2 nebuliser was used in mode I (particle size 0.8-2.0 μm). The results demonstrate the effectiveness of the developed therapy scheme, which allows further use of bactriophage-containing preparations in infectious diseases of animals.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call